论文部分内容阅读
目的:观察腹水浓缩回输治疗失代偿期肝硬化并发自发性细菌性腹膜炎患者的临床疗效及安全性。方法:选择50例失代偿期乙肝肝硬化并发自发性细菌性腹膜炎的患者,给予常规保肝、利尿、支持等治疗的基础上,进行腹水浓缩回输治疗,平均治疗次数为(2.4±0.37)次(B超示少量腹水时停止治疗),疗程为1个月。结果:该治疗可迅速改善患者临床症状和体征,降低腹水多形核白细胞数和改善患者MELD评分,取得很好的疗效,治疗过程中无严重不良事件发生。结论:本次研究为治疗失代偿期肝硬化并发自发性细菌性腹膜炎患者提供了一个新的思维方向,值得在今后临床治疗中进一步探讨使用。
Objective: To observe the clinical efficacy and safety of concentrated ascites reinfusion in the treatment of patients with spontaneous bacterial peritonitis in decompensated cirrhosis. Methods: Fifty patients with decompensated hepatitis B cirrhosis complicated with spontaneous bacterial peritonitis were treated with routine hepatic protection, diuresis and supportive therapy, and the patients were treated with concentrated ascites reinfusion. The average number of treatment was (2.4 ± 0.37 ) Times (B ultrasound showed a small amount of ascites stop treatment), treatment for 1 month. Results: The treatment can rapidly improve the clinical symptoms and signs of patients, reduce ascites polymorphonuclear leukocytes and improve the patient MELD score, and achieved good results, no serious adverse events occurred during the treatment. Conclusion: This study provides a new way of thinking for the treatment of patients with decompensated cirrhosis and spontaneous bacterial peritonitis. It is worth further exploration in future clinical treatment.